AI filing briefs · archive

8-K filings in November 2024, explained

508 material Form 8-K filings that 423 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

14 of 508 briefs match

newest first · times in ET

PSEG Amends Executive Severance and Deferred Compensation Plans

Neutral leadership Written later 5.02

PSEG's Organization and Compensation Committee adopted amendments on November 18, 2024, to its Key Executive Severance Plan and Deferred Compensation Plan as part of a periodic compensation review. The KESP change expands eligible positions to include designated Section 16 Officer positions, and the DCP change extends Core Contribution benefits to certain non-officer highly-compensated employees.

  • Both amendments were adopted November 18, 2024 and took effect the same day.
  • KESP amendment adds designated Section 16 Officer positions to Schedule A, excluding one officer currently on Schedule B.
  • DCP amendment provides Core Contribution benefits to certain highly-compensated non-officer employees, not only officers.
  • Amended plans are filed as Exhibits 10.1 (KESP) and 10.2 (DCP); the filing gives no dollar figures.
Read the filing on SEC.gov ↗
LZLEGALZOOM.COM, INC. Nov 19, 4:32 PM ET

LegalZoom appoints Nathan Gooden, Squarespace CFO, to its board of directors

Neutral leadership Written later 5.027.01

LegalZoom appointed Nathan Gooden as an independent Class I director effective November 19, 2024, and named him to the Audit and Compensation Committees. The Board expanded to six directors, five of whom are independent, and Mr. Gooden currently serves as chief financial officer of Squarespace, Inc.

  • Appointed as independent Class I director effective November 19, 2024, serving until the 2025 Annual Meeting
  • Also appointed to the Audit Committee and the Compensation Committee
  • Board size increased to six directors; five of six are independent
  • Company expects to enter an indemnification agreement with Mr. Gooden
Read the filing on SEC.gov ↗
POWLPOWELL INDUSTRIES INC Nov 19, 4:28 PM ET

Powell Industries Q4 revenue rises 32% to $275 million; net income up 74%

Positive earnings Written later 2.02

Powell Industries reported fiscal fourth-quarter and full-year 2024 results for the period ended September 30, 2024, with revenue and net income up sharply from the prior year. Q4 revenue was down 5% from the third quarter, and full-year net new orders fell to $1.1 billion from $1.4 billion. The filing gives no numeric fiscal 2025 guidance; management only said it expects fiscal 2025 to be another successful year.

  • Q4 revenue of $275 million, up 32% from $208.6 million; diluted EPS of $3.77 vs. $2.17 a year earlier
  • Full-year revenue of $1.0 billion, up 45%; net income of $149.8 million, or $12.29 per diluted share, up 175%
  • Backlog of $1.3 billion at September 30, 2024, essentially unchanged from June 30, 2024 and September 30, 2023
  • Conference call scheduled for Wednesday, November 20, 2024 at 11:00 a.m. Eastern time
Read the filing on SEC.gov ↗
SNEXStoneX Group Inc. Nov 19, 4:24 PM ET

StoneX Group reports record fiscal 2024 net income of $260.8 million, up 9%

Positive earnings Written later 2.02

StoneX Group reported fiscal fourth-quarter 2024 results, with net income of $76.7 million, up 51%, and diluted EPS of $2.32, up 48%, for the quarter ended September 30, 2024. For the full fiscal year, net income rose 9% to $260.8 million and diluted EPS rose 7% to $7.96, which the company called a record annual result. Results were strong across most segments, though the company noted relatively low market volatility.

  • Q4 net operating revenues rose 13% to $454.8 million; quarterly net income was $76.7 million, up 51% from $50.7 million a year earlier
  • Quarterly diluted EPS was $2.32 versus $1.57 a year earlier; ROE was 18.5% for the quarter
  • Full-year net income was $260.8 million, up 9%; full-year diluted EPS was $7.96, up 7%
  • Institutional segment operating revenues rose 30% to $554.1 million in the quarter; OTC derivatives operating revenues fell 23%
Read the filing on SEC.gov ↗
GLGLOBE LIFE INC. Nov 19, 4:24 PM ET

Globe Life adopts executive severance plan covering Co-CEOs and named executive officers

Neutral shareholder Written later 5.02

Globe Life's board adopted an Executive Severance Plan on November 13, 2024, covering Co-CEOs and other Named Executive Officers, and amended its equity award agreement forms. The plan sets cash severance, health coverage and outplacement benefits for qualifying terminations, with larger payments if termination occurs within 24 months after a change in control.

  • Co-CEOs receive cash severance of 2.0 times base salary plus target annual bonus, paid over 24 months, for terminations outside a change-in-control period
  • Other eligible executives receive 1.5 times base salary plus target bonus, paid over 18 months, outside a change-in-control period
  • Within 24 months after a change in control, eligible executives receive a lump sum of 2 times base salary plus target bonus, plus 24 months of health premium payments
Read the filing on SEC.gov ↗
DLBDolby Laboratories, Inc. Nov 19, 4:19 PM ET

Dolby Q4 revenue rises to $305 million; FY2025 revenue outlook $1.33-$1.39 billion

Positive earnings Written later 1.012.022.038.01

Dolby reported fourth-quarter fiscal 2024 revenue of $305 million, up from $291 million a year earlier, and GAAP diluted earnings of $0.61 per share versus $0.09. For the full fiscal year, revenue fell to $1.27 billion from $1.30 billion, while GAAP diluted EPS rose to $2.69 from $2.05. The company also gave fiscal 2025 revenue guidance of $1.33 billion to $1.39 billion and entered a $250 million revolving credit facility with Bank of America, with no amount drawn at closing.

  • Q4 fiscal 2024 revenue $305 million vs. $291 million a year earlier; GAAP diluted EPS $0.61 vs. $0.09
  • Full fiscal 2024 revenue $1.27 billion vs. $1.30 billion; GAAP diluted EPS $2.69 vs. $2.05
  • Fiscal 2025 guidance: total revenue $1.33 billion to $1.39 billion; GAAP diluted EPS $2.43 to $2.58
  • Credit Agreement signed November 14, 2024: $250 million unsecured revolver plus $150 million uncommitted incremental capacity; $0.33 per share dividend payable December 10, 2024
Read the filing on SEC.gov ↗
LZBLA-Z-BOY INC Nov 19, 4:17 PM ET

La-Z-Boy Q2 sales rise 2% to $521 million; adjusted EPS falls to $0.71 from $0.74

Mixed earnings Written later 2.027.01

La-Z-Boy reported fiscal second-quarter 2025 results for the period ended October 26, 2024. Sales rose 2% to $521 million and GAAP diluted EPS rose to $0.71 from $0.63, but non-GAAP diluted EPS fell to $0.71 from $0.74 and non-GAAP operating margin declined to 7.5% from 7.9%. The board also raised the quarterly dividend 10% to $0.22 per share and guided third-quarter sales to $505 million to $525 million.

  • Sales of $521 million, up 2% from $511 million a year earlier; Retail segment delivered sales rose 3% to $222 million
  • GAAP diluted EPS $0.71 vs. $0.63; non-GAAP diluted EPS $0.71 vs. $0.74 (down 4%)
  • Quarterly dividend raised 10% to $0.22 per share, payable December 16, 2024, to holders of record on December 5, 2024
  • Third-quarter outlook: sales of $505 million to $525 million (up 1% to 5%) and non-GAAP operating margin of 6% to 7%
Read the filing on SEC.gov ↗
CVSACovista Inc. Nov 19, 4:10 PM ET

Adtalem: CEO Stephen Beard elected board chairman; shareholders approve all proposals

Neutral leadership Written later 5.025.07

On November 13, 2024, Adtalem's board unanimously elected President and CEO Stephen W. Beard as chairman, so he now holds both roles, succeeding Michael W. Malafronte, who remains on the board as lead independent director. The same day, shareholders elected all ten director nominees and approved the PricewaterhouseCoopers LLP auditor ratification and an advisory vote on executive compensation. The filing names Adtalem Global Education Inc. (NYSE: ATGE), not Covista Inc. (CVSA) as shown in the filing header.

  • November 13, 2024: board unanimously elected CEO Stephen W. Beard as chairman, effective immediately; Malafronte becomes lead independent director.
  • Annual meeting, November 13, 2024: all ten directors elected; Beard received 33,253,740 votes for and 66,330 against.
  • PricewaterhouseCoopers LLP ratification passed with 33,848,340 for and 629,766 against; advisory executive pay vote passed with 31,744,452 for and 847,326 against.
Read the filing on SEC.gov ↗
KEYSKeysight Technologies, Inc. Nov 19, 4:06 PM ET

Keysight posts Q4 net loss of $73 million on $315 million Singapore tax charge

Mixed earnings Written later 2.02

Keysight reported fourth-quarter fiscal 2024 revenue of $1.29 billion, down from $1.31 billion a year earlier, and a GAAP net loss of $73 million, or $0.42 per share, driven by a $315 million tax expense tied to a new Singapore tax incentive. Non-GAAP earnings per share fell to $1.65 from $1.99, and the company guided first-quarter fiscal 2025 revenue to $1.265 billion to $1.285 billion, which matters to shareholders because the charge reduced GAAP results while revenue and adjusted earnings declined.

  • Q4 revenue was $1.29 billion versus $1.31 billion a year earlier; GAAP net loss was $73 million, or $0.42 per share, compared with net income of $226 million, or $1.28 per share.
  • Non-GAAP net income was $288 million, or $1.65 per share, compared with $352 million, or $1.99 per share, in the fourth quarter of 2023.
  • Fiscal 2024 revenue was $4.98 billion versus $5.46 billion; GAAP net income was $0.61 billion, or $3.51 per share.
  • First-quarter fiscal 2025 outlook: revenue of $1.265 billion to $1.285 billion and non-GAAP earnings per share of $1.65 to $1.71.
Read the filing on SEC.gov ↗
PRGPROG Holdings, Inc. Nov 19, 8:15 AM ET

PROG Holdings extends $ credit agreement maturity to November 15, 2029

Neutral financing Written later 1.012.03

PROG Holdings amended its credit agreement on November 15, 2024, extending the maturity date from November 24, 2025 to November 15, 2029. The filing describes the change as a new direct financial obligation and does not disclose changes to borrowing amounts or pricing.

  • Third Amendment signed November 15, 2024 to the credit agreement dated November 24, 2020
  • Maturity date extended from November 24, 2025 to November 15, 2029
  • JPMorgan Chase Bank, N.A. serves as administrative agent
  • Full amendment filed as Exhibit 10.1, with some schedules omitted under Regulation S-K Item 601(a)(5)
Read the filing on SEC.gov ↗
MOG-AMOOG INC. Nov 19, 8:12 AM ET

Moog Inc. COO Mark Trabert to retire December 31, 2024; director Brian Lipke to retire

Neutral leadership Written later 5.02

Moog announced two leadership changes. Chief Operating Officer Mark Trabert plans to retire as COO effective December 31, 2024, and remain an Executive Vice President until retiring in February 2025. Director Brian J. Lipke plans to retire from the Board before the 2025 annual shareholder meeting after 21 years of service.

  • Mark Trabert retires as COO effective December 31, 2024, after a 40-year career with Moog; he stays as EVP until February 2025
  • Operating Group Presidents will report directly to CEO Pat Roche once Trabert's COO role ends
  • Brian J. Lipke intends to retire from the Board immediately before the 2025 annual meeting after 21 years as director
Read the filing on SEC.gov ↗
ENRENERGIZER HOLDINGS, INC. Nov 19, 6:56 AM ET

Energizer fiscal 2024 sales fell 2.5% to $2.9 billion; adjusted EPS rose 7% to $3.32

Mixed earnings Written later 2.028.01

Energizer reported fiscal 2024 net sales of $2,887.0 million, down 2.5% from $2,959.7 million, while adjusted diluted EPS rose to $3.32 from $3.09. Reported net earnings fell to $38.1 million from $140.5 million, mainly due to a $110.6 million non-cash impairment of intangible assets. The company guided fiscal 2025 adjusted EBITDA to $625 million to $645 million and adjusted EPS to $3.45 to $3.65, and its board approved a new buyback of up to 7.5 million shares.

  • Fiscal 2024 net sales were $2,887.0 million, down 2.5%; organic sales declined 2.2%
  • Fiscal 2024 reported diluted EPS was $0.52 versus $1.94; adjusted diluted EPS was $3.32 versus $3.09
  • Fiscal 2025 outlook: adjusted EBITDA of $625 million to $645 million and adjusted EPS of $3.45 to $3.65
  • Board approved a new share repurchase program of up to 7.5 million shares on November 18, 2024, replacing the prior authorization
Read the filing on SEC.gov ↗
JJACOBS SOLUTIONS INC. Nov 19, 6:39 AM ET

Jacobs Q4 revenue rises 4.4% to $3.0 billion; FY25 adjusted EPS outlook $5.80-$6.20

Positive earnings Written later 2.02

Jacobs reported fiscal fourth-quarter 2024 revenue of $3.0 billion, up 4.4% year over year, and GAAP EPS of $2.38, helped by $187 million in mark-to-market gains on its Amentum stock. The company also gave fiscal 2025 guidance for adjusted EPS of $5.80-$6.20, compared with fiscal 2024 adjusted EPS of $5.28, following the completed separation of its Critical Mission Solutions and Cyber & Intelligence businesses into Amentum.

  • Q4 revenue of $2,960,150 thousand, up 4.4%; adjusted net revenue of $2.1 billion, up 4.3%
  • Q4 GAAP EPS of $2.38 versus $0.63 a year earlier; adjusted EPS of $1.37, up 28.0%
  • FY2025 outlook: adjusted EPS of $5.80-$6.20, adjusted EBITDA margin of 13.8-14.0%
  • FY2024 returned $545 million to shareholders through dividends and share repurchases
Read the filing on SEC.gov ↗
CYTKCYTOKINETICS INC Nov 19, 6:02 AM ET

Cytokinetics Licenses Aficamten Rights in Japan to Bayer for €50 Million Upfront

Positive product/contract Written later 1.01

Cytokinetics granted Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan under an agreement signed November 18, 2024. Cytokinetics will receive a €50 million upfront payment, with additional milestone and royalty payments possible, while it keeps the right to run certain clinical trials in Japan.

  • Upfront payment of €50 million from Bayer
  • Milestone payments of up to €90 million tied to clinical and launch events in hypertrophic cardiomyopathy
  • Commercial milestones of up to €490 million plus tiered royalties on Japan net sales, from the high teens to the low thirties percent
  • Agreement dated November 18, 2024; full text to be filed with the 2024 Form 10-K
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.